Entity

Time filter

Source Type


Patent
Epeius Biotechnologies Corporation | Date: 2014-03-14

Nucleic acid sequences encoding improved Herpes Simplex Virus Thymidine Kinases are provided, including their use in diagnostic and therapeutic applications. The thymidine kinases may be mutated using conservative mutations, non-conservative mutations, or both. Also provided are gene therapeutic systems, including viral and retroviral particles.


Patent
Epeius Biotechnologies Corporation | Date: 2014-03-14

Nucleic acid sequences encoding improved Herpes Simplex Virus Thymidine Kinases are provided, including their use in diagnostic and therapeutic applications. The thymidine kinases may be mutated using conservative mutations, non-conservative mutations, or both. Also provided are gene therapeutic systems, including viral and retroviral particles.


Trademark
Epeius Biotechnologies Corporation | Date: 2002-05-31

Pharmaceutical preparations, namely, lesion-targeted vectors carrying immune response genes for use in the treatment of cancer, inflammatory and immunologic disorders.


Trademark
Epeius Biotechnologies Corporation | Date: 2006-10-17

Pharmaceutical preparations, namely, lesion-targeted retroviral vectors for use in the treatment of cancer, cardiovascular and ocular disorders.


Chawla S.P.,Sarcoma Oncology Center | Chua V.S.,Sarcoma Oncology Center | Fernandez L.,Sarcoma Oncology Center | Quon D.,Sarcoma Oncology Center | And 4 more authors.
Molecular Therapy | Year: 2010

Rexin-G, a nonreplicative pathology-targeted retroviral vector bearing a cytocidal cyclin G1 construct, was tested in a phase I/II study for gemcitabine-resistant pancreatic cancer. The patients received escalating doses of Rexin-G intravenously from 1 × 10 11 colony-forming units (cfu) 2-3× a week (dose 0-1) to 2 × 10 11 cfu 3× a week (dose 2) for 4 weeks. Treatment was continued if there was less than or equal to grade 1 toxicity. No dose-limiting toxicity (DLT) was observed, and no vector DNA integration, replication-competent retrovirus (RCR), or vector-neutralizing antibodies were noted. In nine evaluable patients, 3/3 patients had stable disease (SD) at dose 0-1. At dose 2, 1/6 patients had a partial response (PR) and 5/6 patients had SD. Median progression-free survival (PFS) was 3 months at dose 0-1, and 7.65 months at dose 2. Median overall survival (OS) was 4.3 months at dose 0-1, and 9.2 months at dose 2. One-year survival was 0% at dose 0-1 compared to 28.6% at dose 2, suggesting a dose-response relationship between OS and Rexin-G dosage. Taken together, these data indicate that (i) Rexin-G is safe and well tolerated, and (ii) Rexin-G may help control tumor growth, and may possibly prolong survival in gemcitabine-resistant pancreatic cancer, thus, earning US Food and Drug Administration's (FDA) fast-track designation as second-line treatment for pancreatic cancer. © The American Society of Gene & Cell Therapy. Source

Discover hidden collaborations